Curis (CRIS) Announces Additional Data from TakeAim Leukemia Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
LEXINGTON, Mass., April 4, 2024 /PRNewswire/ Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James.
Curis (CRIS) Announces Initial Combination Study Data from its TakeAim Lymphoma Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.